392 related articles for article (PubMed ID: 9827972)
1. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
3. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
Kondo M; Kojima S; Horibe K; Kato K; Matsuyama T
Bone Marrow Transplant; 2001 Apr; 27(7):727-30. PubMed ID: 11360113
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264
[TBL] [Abstract][Full Text] [Related]
7. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U
Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
[TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
9. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.
Ochs LA; Miller WJ; Filipovich AH; Haake RJ; McGlave PB; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471
[TBL] [Abstract][Full Text] [Related]
11. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings.
Ringdén O; Remberger M; Persson U; Ljungman P; Aldener A; Andström E; Aschan J; Bolme P; Dahllöf G; Dalianis T
Bone Marrow Transplant; 1995 Apr; 15(4):619-25. PubMed ID: 7655390
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
[TBL] [Abstract][Full Text] [Related]
15. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A.
Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A
Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746
[TBL] [Abstract][Full Text] [Related]
17. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation.
Eisner MD; August CS
Bone Marrow Transplant; 1995 May; 15(5):663-8. PubMed ID: 7670393
[TBL] [Abstract][Full Text] [Related]
19. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
20. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
